Arcutis Biotherapeutics' Capital Efficiency Challenges

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has a ROIC of -14.38% and a WACC of 13.83%, resulting in a negative ROIC to WACC ratio of -1.04.Comparatively, Black Diamond Therapeutics, Inc. (BDTX) showcases the most efficient capital use among peers with a ROIC of 2.99% and a WACC of 16.85%, leading to a ROIC to WACC ratio of 0.18.Phathom Pharmaceuticals, Inc. (PHAT) exhibits the most severe inefficiency in capital use with a ROIC of -149.31% against a WACC of 8.60%, resulting in a ROIC to WACC ratio of -17.3 ...